ArticleCancers2023

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma.

Erlinda Maria Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.